| 8.7 -0.18 (-2.03%) | 01-14 09:35 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.21  |
1-year : | 28.8 |
| Resists | First : | 18.16 |
Second : | 24.65 |
| Pivot price | 11.05 |
|||
| Supports | First : | 7.65 | Second : | 6.37 |
| MAs | MA(5) : | 9.12 |
MA(20) : | 13.04 |
| MA(100) : | 24.23 |
MA(250) : | 310.41 |
|
| MACD | MACD : | -3.5 |
Signal : | -3.5 |
| %K %D | K(14,3) : | 12.2 |
D(3) : | 12.7 |
| RSI | RSI(14): 26.4 |
|||
| 52-week | High : | 1807.19 | Low : | 7.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ APVO ] has closed above bottom band by 35.4%. Bollinger Bands are 52.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.03 - 9.08 | 9.08 - 9.12 |
| Low: | 8.49 - 8.55 | 8.55 - 8.6 |
| Close: | 8.79 - 8.88 | 8.88 - 8.96 |
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Fri, 09 Jan 2026
Aptevo Therapeutics (APVO) Secures $60 Million Equity Line - GuruFocus
Fri, 09 Jan 2026
Aptevo Therapeutics Secures $60 Million Equity Financing Facility - TipRanks
Fri, 09 Jan 2026
Aptevo Therapeutics Signs Standby Equity Purchase Agreement With Yorkville - TradingView — Track All Markets
Fri, 09 Jan 2026
Biotech lines up $60M to keep next-wave cancer drugs moving to 2029 - Stock Titan
Mon, 29 Dec 2025
Aptevo Therapeutics To Implement 1-for-18 Reverse Stock Split - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 935380 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 43 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -79.2 % |
| Return on Equity (ttm) | -242.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 242958 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.86408e+007 |
| Qtrly Earnings Growth | 758.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | 1.26 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.55 |
| Dividend | 0 |
| Forward Dividend | 57410 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|